CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-stage study tests a combination of two drugs—trastuzumab deruxtecan (DS-8201a) and ceralasertib—in people with advanced solid tumors that have a HER2 mutation. The first part finds the safest dose and checks side effects. The second part compares the combo to DS-8201a …
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
Immunotherapy combo shows promise in Hard-to-Treat stomach cancer
Disease control OngoingThis early-stage trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help control advanced gastroesophageal cancer that cannot be surgically removed. The study enrolled 16 participants and aims to see if the combination can make the c…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New way to deliver chemo shows promise for stomach cancer patients
Disease control OngoingThis early-phase study tests a chemotherapy drug called paclitaxel, given directly into the abdomen, for people with advanced stomach cancer that has spread to the lining of the belly. The main goal is to find the safest dose and understand side effects. About 27 adults with this…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of sonidegib combined with pembrolizumab in 36 adults with advanced solid tumors (cancers that have spread). Sonidegib blocks enzymes that help tumors grow, while pembrolizumab boosts the immune system to attack cancer. The go…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Stomach cancer combo fails to shrink tumors in early trial
Disease control OngoingThis study tested a combination of two drugs, berzosertib and irinotecan, in 17 people with advanced stomach or gastroesophageal junction cancer that had a specific genetic change (TP53 mutation) and was no longer responding to other treatments. The goal was to see if the combina…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC
-
Massive biobank aims to unlock Cancer's secrets
Knowledge-focused OngoingThis study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will track these samples over time to learn how cancer changes and why some treatments stop working. The goal is to build a resource for futu…
Matched conditions: CLINICAL STAGE IV GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:55 UTC